# Posit Science

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/posit-science

- Industry: Healthcare IT
- Headquarters: San Francisco, US
- Website: www.positscience.com
- Total disclosed funding: $43M
- Latest round: Series E (Oct 16, 2012)
- Investors on record: 4

## About

Posit Science specializes in cognitive training through its flagship product, BrainHQ, which enhances mental agility and cognitive functions using research-driven methodologies.Founded in 2002 in San Francisco, US, Posit Science focuses on developing brain training solutions. The company was co-founded by Jeff Zimman and Michael Merzenich, both recognized in the field of neuroscience. In October 2012, they secured USD 1.75 mn in Series E funding from Draper Fisher Jurvetson, raising their total amount raised to USD 1.75 mn, with a current company valuation of USD 6.105 mn.BrainHQ, developed by Posit Science, offers a comprehensive brain training program that leverages over 30 years of research in brain science and neuroplasticity. The core product consists of a series of online exercises designed to enhance cognitive functions such as attention, memory, brain speed, people skills, navigation, and intelligence. Each exercise is adaptive, adjusting in difficulty based on the user’s performance, and typically takes under five minutes to complete. BrainHQ is accessible on various platforms, including computers and mobile devices, catering to a diverse client base that includes individuals seeking to improve their cognitive health and mental agility. The program is marketed primarily in the United States, with potential outreach to international markets, focusing on users interested in enhancing their mental capabilities for personal or professional reasons.BrainHQ operates on a subscription-based revenue model, where users can select from various pricing plans for access to its brain training exercises. The primary transaction structure involves direct-to-consumer sales, allowing individuals to purchase subscriptions directly through the website. Revenue is generated through annual subscription fees, which include promotional discounts for new users, such as a 50% discount for the first year. The service emphasizes long-term engagement by encouraging users to set personal training goals and track their progress, fostering continued usage and renewals. This model aligns with the company’s mission to provide ongoing cognitive training and improvement for its clientele.In October 2012, Posit Science raised USD 1.75 mn in Series E funding from Draper Fisher Jurvetson and other unspecified investors. This funding will be utilized to enhance existing products and explore new markets for their cognitive training solutions. The company is focused on expanding its reach into international markets where demand for cognitive enhancement is growing, targeting specific regions by 2024.

## Funding rounds

- Series E, Oct 16, 2012, $1.8M — Draper Fisher Jurvetson
- Series E, Mar 29, 2011, $1M — Aberdare Ventures
- Series D, Sep 22, 2010, $0.5M — Draper Fisher Jurvetson
- Series D, Dec 23, 2009, $2.8M — Draper Fisher Jurvetson, VSP Capital, Aberdare Ventures
- Series C, May 12, 2009, $5.5M — Draper Fisher Jurvetson, VSP Capital, Aberdare Ventures, GC&H Investments
- Series B, Nov 28, 2006, $7.3M — Draper Fisher Jurvetson
- Series B, Sep 6, 2006, $1.8M — Draper Fisher Jurvetson, VSP Capital, Aberdare Ventures
- Series B, Jun 24, 2005, $15M — Draper Fisher Jurvetson, VSP Capital, Aberdare Ventures
- Series A, Nov 12, 2003, $1M — Draper Fisher Jurvetson
- Series A, Sep 26, 2003, $7.1M — Draper Fisher Jurvetson, VSP Capital, Aberdare Ventures

## Investors

- Draper Fisher Jurvetson (https://capitalatlas.ai/funds/draper-fisher-jurvetson) — Series A, Series B, Series C, Series D, Series E
- VSP Capital (https://capitalatlas.ai/funds/vsp-capital) — Series A, Series B, Series C, Series D
- Aberdare Ventures (https://capitalatlas.ai/funds/aberdare-ventures) — Series A, Series B, Series C, Series D, Series E
- GC&H Investments (https://capitalatlas.ai/funds/gc-h-investments) — Series C